View Older Stories View More Recent Stories

May 1, 2018 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights
May 1, 2018 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights
May 1, 2018 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights
Apr 30, 2018 07:31AM Spark Therapeutics (ONCE) Sells Priority Review Voucher for $110 Million
Apr 30, 2018 07:30AM Spark Therapeutics Sells Priority Review Voucher for $110 Million
Apr 30, 2018 07:30AM Spark Therapeutics Sells Priority Review Voucher for $110 Million
Feb 23, 2018 07:30AM Spark Therapeutics to Participate in Multiple Conferences in March
Feb 23, 2018 07:30AM Spark Therapeutics to Participate in Multiple Conferences in March
Feb 23, 2018 07:30AM Spark Therapeutics to Participate in Multiple Conferences in March
Feb 20, 2018 07:30AM Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress
Feb 20, 2018 07:30AM Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress
Feb 13, 2018 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights
Feb 13, 2018 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights
Feb 13, 2018 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights
Feb 5, 2018 07:30AM Spark Therapeutics to Participate in Multiple Conferences in February
Feb 5, 2018 07:30AM Spark Therapeutics to Participate in Multiple Conferences in February
Feb 5, 2018 07:30AM Spark Therapeutics to Participate in Multiple Conferences in February
Jan 24, 2018 04:00PM Spark Therapeutics (ONCE) Reports Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside U.S.
Jan 24, 2018 04:00PM Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.
Jan 24, 2018 04:00PM Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.
Jan 24, 2018 04:00PM Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.
Jan 4, 2018 07:33AM Spark Therapeutics (ONCE) Appoints Robert Perez to Board
Jan 4, 2018 07:30AM Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors
Jan 4, 2018 07:30AM Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors
Jan 4, 2018 07:30AM Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors
Jan 3, 2018 08:31AM Spark Therapeutics (ONCE) Announces Three New Payer Programs to Improve Patient Access to LUXTURNA (voretigene neparvovec-rzyl)
Jan 3, 2018 08:30AM Spark Therapeutics Announces First-of-their-kind Programs to Improve Patient Access to LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment
Jan 3, 2018 08:30AM Spark Therapeutics Announces First-of-their-kind Programs to Improve Patient Access to LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment
Jan 2, 2018 07:30AM Spark Therapeutics to Participate in Multiple Conferences in January
Jan 2, 2018 07:30AM Spark Therapeutics to Participate in Multiple Conferences in January
Jan 2, 2018 07:30AM Spark Therapeutics to Participate in Multiple Conferences in January
Dec 19, 2017 03:13PM FDA Approves Spark Therapeutics' LUXTURNA(TM) (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
Dec 19, 2017 03:13PM Spark Therapeutics (ONCE) Confirms FDA Approval of its LUXTURNA, One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
Dec 19, 2017 03:05PM FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
Dec 19, 2017 03:05PM FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
Dec 11, 2017 07:47AM Spark Therapeutics (ONCE) Reports Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A
Dec 11, 2017 07:45AM Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and Expo
Dec 11, 2017 07:45AM Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and Expo
Dec 11, 2017 07:10AM Spark Therapeutics (ONCE) and Pfizer (PFE) Announce L-T Prelim. Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at ASH Meeting
Dec 11, 2017 07:00AM Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Ex
Dec 11, 2017 07:00AM Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Ex
Dec 6, 2017 05:01PM Spark Therapeutics (ONCE), Pfizer (PFE) Announce Publication in NEJM of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
Dec 6, 2017 05:00PM Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
Dec 6, 2017 05:00PM Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
Dec 5, 2017 07:30AM Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59th American Society of Hematology Annual Meeting and Exposition
Nov 13, 2017 05:45AM Spark Therapeutics (ONCE) Reports Three-Year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational LUXTURNA (voretigene neparvovec)
Nov 10, 2017 05:05PM Three-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational LUXTURNA™ (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inh
Nov 7, 2017 07:30AM Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress
Nov 7, 2017 07:16AM Spark Therapeutics (ONCE), Pfizer (PFE) Amend Pact for Investigational SPK-9001 in Hemophilia B
Nov 7, 2017 07:15AM Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B
View More Recent Stories View Older Stories